Please assess the completion status of the following clinical trial:

Trial Title: DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, 18 to 75 years of age~* Overweight or obese with a body mass index (BMI) ≥ 25 kg/m2~* Presumed NASH diagnosed by prior biopsy and/or imaging criteria~* Written informed consent~Key Exclusion Criteria:~* History or clinical evidence of chronic liver diseases other than NAFLD~* History or known clinical evidence of cirrhosis, esophageal varices, hepatic decompensation or other severe liver impairment,~* History of liver transplant, or current placement on a liver transplant list~* Current diagnosis or history of pituitary or thyroid disorders - except for patients with primary hypothyroidism on a stable dose of thyroid hormone replacement therapy.~* Abnormal TSH or free T4 levels~* Weight loss of \> 5% total body weight within 3 months prior to Screening~* Uncontrolled diabetes~* Uncontrolled hyperlipidemia~* Unstable cardiovascular disease~* Excessive alcohol consumption~Other protocol-defined I/E criteria that apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: TERN-501 1 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 2: TERN-501 3 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 3: TERN-501 6 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 4: TERN-501 3 mg + TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 5: TERN-501 6 mg + TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 6:TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 7: Matching placebo (Type: PLACEBO_COMPARATOR): Orally administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).